Jeffrey Tyner
Impact in
- Hematology top 0.2%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Genetics top 0.2%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
Papers in
- Hematology 144
- Acute Myeloid Leukemia Research 100
- Chronic Myeloid Leukemia Treatments 67
-
- Protein Degradation and Inhibitors 35
- Histone Deacetylase Inhibitors Research 15
- Co-authors
- Brian Druker (123 shared papers)Marc Loriaux (50 shared papers)Julia E. Maxson (20 shared papers)Michael W. Deininger (24 shared papers)Christopher A. Eide (54 shared papers)Shannon K. McWeeney (54 shared papers)Anupriya Agarwal (36 shared papers)Bill H. Chang (35 shared papers)
- Journals
- Blood (90 papers)Cancer Research (23 papers)Leukemia (11 papers)Oncotarget (7 papers)Clinical Cancer Research (7 papers)
- Partner nations
- United StatesIndiaSingapore
In The Last Decade
Jeffrey Tyner
229 papers receiving 7.2k citations
Jeffrey Tyner's Hit Papers
Peers
Comparison fields: 5 of 120
- Hematology 2.7k
- Genetics 1.9k
- Immunology 1.2k
- Oncology 1.2k
- Cancer Research 644
Countries citing papers authored by Jeffrey Tyner
This map shows the geographic impact of Jeffrey Tyner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Tyner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Tyner more than expected).
Fields of papers citing papers by Jeffrey Tyner
This network shows the impact of papers produced by Jeffrey Tyner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Tyner. The network helps show where Jeffrey Tyner may publish in the future.
Co-authors
The 25 scholars most cited alongside Jeffrey Tyner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 244 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Hit paper breakdown → | 2010 | 592 |
| 2 | OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML Hit paper breakdown → | 2013 | 360 |
| 3 | 2005 | 235 | |
| 4 | 2019 | 233 | |
| 5 | 2006 | 217 | |
| 6 | 2010 | 187 | |
| 7 | 2017 | 184 | |
| 8 | 2016 | 171 | |
| 9 | 2013 | 160 | |
| 10 | 2012 | 128 | |
| 11 | 2020 | 127 | |
| 12 | 2013 | 119 | |
| 13 | 2011 | 111 | |
| 14 | 2015 | 108 | |
| 15 | 2014 | 104 | |
| 16 | 2012 | 103 | |
| 17 | 2008 | 103 | |
| 18 | 2016 | 98 | |
| 19 | 2002 | 97 | |
| 20 | 2015 | 96 |
About Jeffrey Tyner
Jeffrey Tyner is a scholar working on Hematology, Molecular Biology, Genetics, Oncology and Immunology, having authored 244 papers that have together received 7.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (100 papers), Chronic Myeloid Leukemia Treatments (67 papers), Chronic Lymphocytic Leukemia Research (53 papers), Protein Degradation and Inhibitors (35 papers), Acute Lymphoblastic Leukemia research (31 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (28 papers), Histone Deacetylase Inhibitors Research (15 papers) and CAR-T cell therapy research (15 papers). The work is most often cited by research in Hematology (2.7k citations), Genetics (1.9k citations), Immunology (1.2k citations), Oncology (1.2k citations) and Cancer Research (644 citations). Jeffrey Tyner has collaborated with scholars based in United States, India and Singapore. Frequent co-authors include Brian Druker, Marc Loriaux, Julia E. Maxson, Michael W. Deininger, Christopher A. Eide, Shannon K. McWeeney, Anupriya Agarwal, Bill H. Chang, Elie Traer and Jason Gotlib. Their work appears in journals such as Blood, Cancer Research, Leukemia, Oncotarget and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.